Company: INKT
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001193125-25-159014
Chunk: 17

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 17
---
. As of November 2, 2022, the aggregate market value of our outstanding common stock held by non-affiliates,or our public float, was approximately $13,915,511 million based on 33,785,929 shares of outstanding common stock as of such date, at a price of $2.92 per share on September 8, 2022, which was the highest closing sale price of our common stock on the Nasdaq Capital Market within 60 days of the filing date of this registration statement. We have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 duringthe prior 12 calendar month period that ends on and includes the date of this prospectus. Pursuant to General Instruction I.B.6 of Form S-3, inno event will we sell securities registered on this registration statement in a public primary offering with a value exceeding more than one-third ofour public float in any 12-month periodso long as our public float remains below $75.0 million. Investing in our securities involves a high degree of risk. Risks associated with an investment in our securities will be described in the applicable prospectus supplement and certain of our filings with the Securities and Exchange Commission incorporated by reference into this prospectus, as described under “ Risk Factors” on page 4. You should read this prospectus and any applicable prospectus supplement together with additional information described under the heading “Where You Can Find More Information” before you make your investment decision. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The date of this prospectus is November 8, 2022.

TABLE OF CONTENTS

| ABOUT THIS PROSPECTUS                                |     |  1 |
| SUMMARY                                              |     |  3 |
| RISK FACTORS                                         |     |  4 |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS |     |  5 |
| USE OF PROCEEDS                                      |     |  7 |
| PLAN OF DISTRIBUTION                                 |     |  8 |
| GENERAL DESCRIPTION OF SECURITIES                    |     | 11 |
| DESCRIPTION OF OUR COMMON STOCK                      |     | 12 |
| DESCRIPTION OF OUR PREFERRED STOCK                   |     | 15 |
| DESCRIPTION OF OUR WARRANTS                          |     | 16 |
| DESCRIPTION OF OUR DEBT SEC